Replies to post #88751 on Amarin Corp Plc (AMRN)

[jfmcrr]

Jeeze... That's kind of a strange view...

That's how investors get themselves into trouble, by over-extending an interpretation of "trends."

For a biotech investor/speculator.

The sector is rife with blown up companies and failed studies and insanely successful insane gambles. Ya can't place money here without the possibility of losing a big chunk of it and maybe making a huge pile. Or not. Ya find something with possibilities and ya throw yer dollar down and hope. Counseling caution here about Reduce It is jawjacking as the plane levels off and the skydivers line up. Both sides of Reduce It predictions and hopes have been represented here. We'll all know the answer inna future. 'till then, we'll all pontificate and strike poses. Great fun. Doesn't change much.....

For now, most of the verbiage entertains.

Have a kickass weekend, all ya all.

[TastyTheElf]

Dude you really want to do this, after your CYTR train wreck?

Do you remember what a cocky bully you were about your modeling? Remind me what the PRECISE probabilities were of each p-value outcome?

Do you know what the acronym FOS stands for?

I lost 6%. What did you lose?

[HDGabor]

P-

Nothing is wrong opposite (negative) opinion ... if it is (at least) logical ...

Impossible to list everything, so it will be just few example:
- you could not separate FDA approach from FDA sponsored / supported) publication regarding ARR
- it looks like you do not have a clue about R-IT (mean TG below 200 and high LDL.C acc. to you)
- all patients in R-IT wre advised perfectly ... yes, if the health systems are the same in the US and (e.g.) in Ukraine ...
- refer to MARINE / ANCHOR / JELIS data full with mistakes ... e.g. meanwhile M EPA baseline level was higher (app. 2 times than A) it was still app. 50% of JELIS
- meanwhile you could find one "relevant" study only, you do not think that try to figure out (not modelling!) R-IT event rate is waste of time ...
- Because you think the final p-value will be worse than p=0.17, you don't think the RRR will be better than 5% ... what? ... you have a strong opinion about p, but not about event rates ... Furthermore p determines RRR acc. to you ...
- You could not find anything about CHERRY trial other than AMRN's PR, so it was sponsored by Amarin ...

and the list could be continued. Your argument does not have any basis sometimes or controversial with your previous argument *e.g. JELIS is useless .... unless if you could pick up something to back up your word).

I agree with you that real investor could not be influenced by FUD / board post (so I do not think you have an agenda), but if you have ... please, do us a favor: invest in some times, check / learn the topic, make notes and be / stay consistent.

Again: Personally I more than welcome opposite / negative view, but please, include some value (starting with basic knowledge about Amarin and R-IT).

Best,
G

[VuBru]

True - Trends do not indicate significance. But, you then have to look at sample size. If the effect size (RRR) stays roughly similar across studies, a trend quickly becomes "highly significant" if you add a bunch of extra patients. R-IT has 8,000, and the studies you are referring to have how many?